Oric Pharmaceuticals share price today

(ORIC)

Oric Pharmaceuticals share price is $9.56 & ₹809.19 as on 6 Dec 2024, 2.30 'hrs' IST

$9.56

▲

-0.24

(-2.45%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Oric Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Oric Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Oric Pharmaceuticals. Get details on the Indian mutual funds that are investing in Oric Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Oric Pharmaceuticals's financials.

Oric Pharmaceuticals share price movements

$9.53
$9.80
$9.56
0.37%
Downside
Day's Volatility :2.81%
Upside
2.45%
$6.33
$16.65
$9.56
33.79%
Downside
52 Weeks Volatility :61.98%
Upside
42.58%

Oric Pharmaceuticals Returns

Period	Oric Pharmaceuticals	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.93%	-5.7%	0.0%
6 Months	8.27%	-0.8%	0.0%
1 Year	3.02%	9.9%	0.0%
3 Years	-36.69%	10.7%	-19.7%

Oric Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$9.8
Open	$9.72
Today's High	$9.8
Today's Low	$9.525
Market Capitalization	$674.6M
Today's Volume	$193.7K
52 Week High	$16.65
52 Week Low	$6.33
Revenue TTM	$0.0
EBITDA	$-133.7M
Earnings Per Share (EPS)	$-1.78
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-45.98%

How to invest in Oric Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Oric Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Oric Pharmaceuticals stock in both rupees (INR) and dollars (USD). Search for Oric Pharmaceuticals or ORIC on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Oric Pharmaceuticals or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Oric Pharmaceuticals shares which would translate to 0.089 fractional shares of Oric Pharmaceuticals as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Oric Pharmaceuticals

-31%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Oric Pharmaceuticals on INDmoney from India has reduced in the last 30 days as on Dec 6, 2024. -31% less investors are searching Oric Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Oric Pharmaceuticals

Nextech Invest AG
7.49%
BlackRock Inc
6.85%
VR Adviser, LLC
6.23%
FMR Inc
6.21%
Viking Global Investors LP
5.67%
Alkeon Capital Management, LLC
5.53%

Analyst Recommendation on Oric Pharmaceuticals

Buy

93%Buy

6%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Oric Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Oric Pharmaceuticals

What analysts predicted

Upside of 95.89%

Current:

$9.56

Target:

$18.73

Insights on Oric Pharmaceuticals

Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 43.9% return, outperforming this stock by 37.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 76.3%

Oric Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Oric Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Oric Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Oric Pharmaceuticals	-7.18%	8.27%	3.02%	-36.69%	-62.9%
Regeneron Pharmaceuticals, Inc.	-5.97%	-23.44%	-9.57%	20.91%	110.02%
Biontech Se	11.44%	18.44%	16.6%	-60.74%	309.79%
Alnylam Pharmaceuticals, Inc.	-7.77%	64.82%	42.06%	39.68%	108.61%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.79%	29.94%	124.11%	109.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Oric Pharmaceuticals	NA	NA	NA	-1.87	-0.46	-0.29	NA	3.88
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Oric Pharmaceuticals	Buy	$674.6M	-62.9%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	110.02%	18.56	33.61%
Biontech Se	Buy	$28.5B	309.79%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.61%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	109.65%	32.84	-4.51%

About Oric Pharmaceuticals

oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.

Organization	Oric Pharmaceuticals
Employees	112
CEO	Dr. Richard A. Heyman Ph.D.
Industry	Health Technology

Management People of Oric Pharmaceuticals

Name	Title
Dr. Richard A. Heyman Ph.D.	Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director
Mr. Dominic G. Piscitelli CPA, M.B.A.	Chief Financial Officer
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board
Dr. Scott W. Lowe Ph.D.	Co-Founder & Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D.	General Counsel
Mr. Daniel Iazzetti	VP & Head of People
Dr. Edna Chow Maneval	Senior Vice President of Clinical Development

Important FAQs about investing in Oric Pharmaceuticals from India :

What is Oric Pharmaceuticals share price today?

Oric Pharmaceuticals (ORIC) share price today is $9.56.

Can Indians buy Oric Pharmaceuticals shares?

Yes, Indians can invest in the Oric Pharmaceuticals (ORIC) from India.

With INDmoney, you can buy Oric Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Oric Pharmaceuticals at zero transaction cost.

How can I buy Oric Pharmaceuticals shares from India?

It is very easy to buy Oric Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Oric Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Oric Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Oric Pharmaceuticals stocks?

To start investing in Oric Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.